Tag: Alzheimer’s disease

April 11, 2024

The pTau217 plasma biomarker test, which runs on Roche’s widely-used Elecsys analysers, is intended to look for the presence or absence of amyloid pathology in individuals with suspected Alzheimer’s. pTau217 is a phosphorylated fragment of the protein tau that in […]

August 9, 2023

In the ongoing search for a cure for Alzheimer’s disease, a burgeoning branch of medicine is bringing new hope. Stem cell therapies are already being used to treat various cancers and disorders of the blood and immune system. In a […]

July 7, 2023

The drug, Leqembi (lecanemab-irmb), was authorised for use in patients with mild cognitive impairment (MCI) or early-stage Alzheimer’s disease earlier this year through the accelerated approval pathway, under which the FDA may approve drugs for serious conditions where there is […]

May 11, 2023

Today, the U.S. Food and Drug Administration is announcing the supplemental approval of Rexulti (brexpiprazole) oral tablets for the treatment of agitation associated with dementia due to Alzheimer’s disease. This is the first FDA-approved treatment option for this indication. “Agitation […]

January 9, 2023

The downturn that struck the biotechnology industry in 2022 wasn’t just about tumbling stock prices. The sector also won only 37 new drug approvals from the Food and Drug Administration’s main review office last year, its lowest total since 2016. […]

January 3, 2023

The biotechnology industry begins 2023 at a crossroads. In many ways, the sector is coming off of one of its toughest years in recent memory. Initial public offerings ground to a halt. A widely followed biotech stock index plunged nearly […]

December 27, 2022

Spatial biology’s technological advances over the past few years have deepened researchers’ ability to ask biological questions. However, limitations remain. For example, methods are lacking for the molecular analysis of large biological specimens imaged in 3D. Now, a novel spatial […]

December 16, 2022

Scientists at Scripps Research and Massachusetts Institute of Technology (MIT) have found a clue to the molecular cause of Alzheimer’s disease (AD), which may also explain why women are at greater risk for the disease than men. The team found […]

December 15, 2022

A new study by the University of Colorado Anschutz Medical Campus demonstrates viruses can inflame and disrupt connections between the olfactory system, and the part of the brain associated with memory and learning, which may accelerate the onset of Alzheimer’s […]

December 1, 2022

“Most people probably think that inflammation in the brain is something bad and that you should inhibit the inflammatory system in case of illness. But inflammation doesn’t just have to be negative,” explained Joana B. Pereira, a researcher at Lund […]

November 30, 2022

The results of research headed by a team at Shanghai Jiao Tong University have identified formic acid as a sensitive urinary biomarker that can reveal early-stage Alzheimer’s disease (AD). The findings could potentially pave the way for inexpensive and convenient […]

November 7, 2022

A computational study conducted on genetic data from 5.62 million ethnically diverse individuals over 60 years of age, found moderate or high use of temisartan, a drug currently prescribed for people with high blood pressure, is associated with lower risk […]

October 5, 2022

A study in mice and human brain tissue by researchers at Case Western Reserve University has uncovered a mechanism that may explain the sex-based differences in Alzheimer’s disease, and also suggest why females are more vulnerable. The work found that […]

September 26, 2022

Collaborating researchers at Aarhus University’s department of biomedicine and department of clinical medicine have harnessed CRISPR-Cas9 gene editing technology to generate a herd of Göttingen minipigs that could help to advance Alzheimer’s disease (AD) research and potentially unlock future treatment […]

September 14, 2022

A hormone called irisin, which is secreted into the blood during aerobic exercise, has been found to reduce levels of alpha synuclein, a protein linked to Parkinson’s disease (PD), and halt movement problems in mice. The new work could pave […]

September 8, 2022

A newly developed antibody that increases the activation of TREM2—a receptor on microglia—reduces amyloid burden and alleviates cognitive decline in mice exhibiting Alzheimer’s disease (AD) pathology. These findings indicate that the antibody, Ab18 TVD-Ig/aTfR, may have promise as a treatment […]

July 5, 2022

Can the biotechnology industry regain its footing after months of sliding stock values and setbacks? Recently, there have been some positive signs. Dealmaking has picked up. Drug pricing reform — a persistent concern for the industry and its investors — […]

April 28, 2022

Sio has changed significantly since its formation in 2014. Then, it was Axovant, one of the many subsidiaries built around Roivant Sciences, a healthcare company created by the well-known hedge fund partner Vivek Ramaswamy. Like other “vant” companies, Axovant aimed […]

March 14, 2022

Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced today the U.S. Food and Drug Administration (FDA) has approved Corium’s Adlarity (donepezil transdermal system) as a treatment for patients with […]

December 27, 2021

Biogen and Eisai’s Alzheimer’s disease treatment-in-waiting, lecanemab, has been granted a fast-track tag by the FDA, setting up a potentially swift path through the regulatory process. The drug is the next in line behind the pair’s approved therapy Aduhelm, which […]